A Study of PRN1008 in Patients With Pemphigus

Exclusion Criteria

• •Suspected paraneoplastic pemphigus and other forms of pemphigus that were not PV or PF.
• •Previous use of a Bruton tyrosine kinase inhibitor.
• •Pregnant or lactating women.
• •Electrocardiogram clinically significant abnormalities.
• •A history of malignancy of any type within 5 years before Day 1, other than surgically excised non-melanoma skin cancers or in situ cervical cancer.
• •Use of immunologic response modifiers as concomitant medication and with the washout period.
• •Use of proton pump inhibitor drugs such as omeprazole and esomeprazole within 3 days of Day 1.
• •Concomitant use of known strong-to-moderate inducers or inhibitors of cytochrome P450 3A (CYP3A) within 3 days or 5 half-lives (whichever is longer) of Day 1
• •Use of CYP3A-sensitive substrate drugs.
• •Had received any investigational drug within the 30 days before Day 1.
• •History of drug abuse within the previous 12 months.
• •Alcoholism or excessive alcohol use.
• •Any other clinically significant disease, condition or medical history that, in the opinion of the Investigator, would interfere with participant safety, trial evaluations, and/or trial procedures.